Search in:

Advanced search

Expert Review of Vaccines Volume 15, 2016 - Issue 2

Submit an article Journal homepage

767

Views

CrossRef citations to date

Altmetric

Reviews

Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy

Juejing LingDepartment of Pharmaceutical Sciences, University of Toronto, Hospital for Sick Children, Toronto, Ontario, Canada

https://orcid.org/0000-0002-4383-713X

Gideon KorenDepartment of Pharmaceutical Sciences, University of Toronto, Hospital for Sick Children, Toronto, Ontario, CanadaCorrespondence[email protected]

Pages 239-256 | Received 29 Jun 2015, Accepted 29 Oct 2015, Published online: 07 Dec 2015

Cite this article
https://doi.org/10.1586/14760584.2016.1115351
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

References

Papers of special note have been highlighted as:
Google Scholar
• of interest
Google Scholar
•• of considerable interest
Google Scholar
Morrow T, Felcone LH. Defining the difference: what makes biologics unique. Biotechnol Healthc [Internet]. 2004;1(4):24–29. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3564302&tool=pmcentrez&rendertype=abstract
PubMedGoogle Scholar
Malviya G, Salemi S, Bruno L, et al. Biological therapies for rheumatoid arthritis: progress to date. BioDrugs. 2013;27(4):329–345.
PubMed Web of Science ®Google Scholar
Nielsen OH, Jess T. IBD: can TNF inhibitors be administered during the third trimester? Nat Rev Gastroenterol Hepatol [Internet]. 2013;10(3):130–131. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23247511
PubMed Web of Science ®Google Scholar
Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol [Internet]. 2013;19(17):2591–2602. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3645377&tool=pmcentrez&rendertype=abstract
PubMed Web of Science ®Google Scholar
Nielsen OH, Loftus EV, Jess T. Safety of TNF-α inhibitors during IBD pregnancy: a systematic review. BMC Med [Internet]. 2013;11(1):174. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3734216&tool=pmcentrez&rendertype=abstract
PubMed Web of Science ®Google Scholar
Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol [Internet]. 2013;11(3):286–292. DOI:10.1016/j.cgh.2012.11.011.
PubMed Web of Science ®Google Scholar
Zelinkova Z, De Haar C, De Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33(9):1053–1058.
PubMed Web of Science ®Google Scholar
Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:1–13. Article ID 985646. DOI:10.1155/2012/985646.
PubMed Web of Science ®Google Scholar
Guiddir T, Fremond M-L, Triki TB, et al. Anti-TNF-Â therapy may cause neonatal neutropenia. Pediatrics [Internet]. 2014;134(4):e1189–e1193. Available from: http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2014-0054
PubMed Web of Science ®Google Scholar

• Four cases of severe and moderate neonatal neutropenia in newborns exposed to infliximab in utero are described

Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn’s Disease. J Crohns Colitis. 2010;4(5):603–605.
PubMed Web of Science ®Google Scholar
Malek A. Role of IgG antibodies in association with placental function and immunologic diseases in human pregnancy. Expert Rev Clin Immunol [Internet]. 2013;9(3):235–249.
PubMed Web of Science ®Google Scholar
Dancis J, Lind J, Oratz M, et al. Placental transfer of proteins in human gestation. Am J Obstet Gynecol. 1961;82:167–171.
PubMed Web of Science ®Google Scholar
Saji F, Samejima Y, Kamiura S, et al. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod. 1999;4(2):81–89.
PubMedGoogle Scholar
Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol [Internet]. 2009;104(1):228–233.
PubMed Web of Science ®Google Scholar
Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4(10):1255–1258.
PubMed Web of Science ®Google Scholar
Fritzsche J, Pilch A, Mury D, et al. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol. 2012;46(8):718–719.
PubMed Web of Science ®Google Scholar
Ben-Horin S, Yavzori M, Kopylov U, et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis. 2011;5(6):555–558.
PubMed Web of Science ®Google Scholar
Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding? World J Gastroenterol. 2008;14(19):3085–3087.
PubMed Web of Science ®Google Scholar
Julsgaard M, Brown S, Gibson P, et al. Adalimumab levels in an infant. J Crohns Colitis [Internet]. 2013;7(7):597–598. DOI:10.1016/j.crohns.2012.10.009.
PubMed Web of Science ®Google Scholar
Ben-Horin S, Yavzori M, Katz L, et al. Adalimumab level in breast milk of a nursing mother. Clin Gastroenterol Hepatol [Internet]. 2010;8(5):475–476. DOI:10.1016/j.cgh.2009.11.023.
PubMed Web of Science ®Google Scholar
Murashima A, Watanabe N, Ozawa N, et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis [Internet]. 2009;68(11):1793–1794.
PubMed Web of Science ®Google Scholar
Berthelsen BG, Fjeldsøe-Nielsen H, Nielsen CT, et al. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology. 2010;49(11):2225–2227.
PubMed Web of Science ®Google Scholar
Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol. 2004;31(5):1017.
PubMed Web of Science ®Google Scholar
Friedrichs B, Tiemann M, Salwender H, et al. The effects of rituximab treatment during pregnancy on a neonate. Haematologica [Internet]. 2006;91(10):1426–1427. Available from: http://www.haematologica.org/content/91/10/1426.abstract
PubMed Web of Science ®Google Scholar
Haghikia A, Langer-Gould A, Rellensmann G, et al Natalizumab use during the third trimester of pregnancy. JAMA Neurol [Internet]. 2014;71(7):1–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24821217
Web of Science ®Google Scholar
de Lima A, Zelinkova Z, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut [Internet]. 2015;1–8. Available from: http://gut.bmj.com/cgi/doi/10.1136/gutjnl-2015-309321
Google Scholar

• A recently published study with 1-year follow-up outcomes among children born to mothers from anti-tumor necrosis factor (TNF) early stop group, continue group and non-inflammatory bowel disease control group.

Mahadevan U, Kane SV, Church JA, et al. 499 the effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology [Internet]. 2008;134(4):A–69. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0016508508603236
Web of Science ®Google Scholar
Steenholdt C, Ai-Khalaf M, Ainsworth MA, et al. Therapeutic infliximab drug level in a child born to a woman with ulcerative colitis treated until gestation week 31. J Crohns Colitis [Internet]. 2012;6(3):358–361. DOI:10.1016/j.crohns.2011.10.002.
PubMed Web of Science ®Google Scholar
Ostensen M. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann N Y Acad Sci [Internet]. 2014;1317:32–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24840548
PubMed Web of Science ®Google Scholar
Mahadevan U, Miller JK, Wolf DC. Adalimumab levels detected in cord blood and infants exposed in utero. Gastroenterology [Internet]. 2011;140(5):S61–S62. Available from: http://www.sciencedirect.com/science/article/pii/S0016508511602515
Web of Science ®Google Scholar
Martin PL, Oneda S, Treacy G. Effects of an anti-TNF-? Monoclonal antibody, administered throughout pregnancy and lactation, on the development of the Macaque immune system. Am J Reprod Immunol. 2007;58(2):138–149.
PubMed Web of Science ®Google Scholar
Decker M, Rothermundt C, Holländer G, et al. Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol. 2006;7(8):693–694.
PubMed Web of Science ®Google Scholar
Klink DT, Van Elburg RM, Schreurs MWJ, et al. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol. 2008;2008:1–6. Article ID 271363. DOI:10.1155/2008/271363.
PubMed Web of Science ®Google Scholar
Ojeda-Uribe M, Afif N, Dahan E, et al. Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases. Clin Rheumatol. 2013;32(5):695–700.
PubMed Web of Science ®Google Scholar
Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108(April):1426–1438.
PubMed Web of Science ®Google Scholar
Julsgaard M, Christensen LA, Gibson PR, et al. Adalimumab and Infliximab levels in neonates correlate with duration of treatment in pregnancy (ERA study). J Gastroenterol Hepatol. 2014;29:117–118.
Web of Science ®Google Scholar
Zelinkova Z, van der Ent C, Bruin KF, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol [Internet]. 2012;11(3):318–321. DOI:10.1016/j.cgh.2012.10.024.
PubMed Web of Science ®Google Scholar
Mahadevan U, Martin CF, Dubinsky M, et al. 960 exposure to anti-TNFα therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry. Gastroenterology [Internet]. 2014;146(5):S–170. Available from: http://www.gastrojournal.org/article/S0016508514606028/fulltext
Web of Science ®Google Scholar

• A large PIANO registry long-term report on the first-year infection rate of infants prenatally exposed to anti-TNFs and natalizumab

Arsenescu R, Arsenescu V, de Villiers WJS. TNF-α and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol [Internet]. 2011;106(4):559–562. DOI:10.1038/ajg.2011.5.
PubMed Web of Science ®Google Scholar
Djokanovic N, Klieger-Grossmann C, Pupco A, et al. Safety of infliximab use during pregnancy. Reprod Toxicol [Internet]. 2011;32(1):93–97.
PubMed Web of Science ®Google Scholar
Johnsson A, Avlund S, Grosen A, et al. Chicken pox infection in a three months old infant exposed in utero to Adalimumab. J Crohn’s Colitis [Internet]. 2013;7(3):e116–e117. DOI:10.1016/j.crohns.2012.07.020.
PubMedGoogle Scholar
Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology [Internet]. 2007;46(4):695–698.
PubMed Web of Science ®Google Scholar
Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther [Internet]. 2014;40(4):363–373. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24980270
PubMed Web of Science ®Google Scholar
Seirafi M, Treton X, Vroey BD, et al. Anti-TNF therapy and pregnancy in inflammatory bowel disease: a prospective cohort study from the GETAID. Gastroenterology [Internet]. 2011;140(5):S–175. DOI:10.1016/S0016-5085(11)60708-7.
Web of Science ®Google Scholar
Bortlik M, Duricova D, Machkova N, et al. Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflamm Bowel Dis [Internet]. 2014;20(3):495–501. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24407486
PubMed Web of Science ®Google Scholar

• A long-term study on the immune development of infants prenatally exposed to anti-TNF agents

Mahadevan U, Martin CF, Sandler RS, et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology [Internet]. 2012;142(5):S–149. Available from: http://www.gastrojournal.org/article/S0016508512605617/fulltext
Web of Science ®Google Scholar
Bessissow T, Renard M, Hoffman I, et al. Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther [Internet]. 2012;36(4):312–323. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22725726
PubMed Web of Science ®Google Scholar
Liu JH, Wei S, Lamy T, et al. Chronic neutropenia mediated by fas ligand. Blood [Internet]. 2000;95(10):3219–3222. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10807792
PubMed Web of Science ®Google Scholar
Coakley G, Iqbal M, Brooks D, et al. CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty’s and large granular lymphocyte syndromes. Arthritis Rheum. 2010;43(4):834.
Web of Science ®Google Scholar
Keystone EC. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am [Internet]. 2001;27(2):427–443. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11396102
PubMed Web of Science ®Google Scholar
Ton E, Tekstra J, Hellmann PM, et al. Safety of rituximab therapy during twins’ pregnancy. Rheumatology. 2011;50(4):806–808.
PubMed Web of Science ®Google Scholar
Gall B, Yee A, Berry B, et al. Rituximab for management of refractory pregnancy-associated immune thrombocytopenic purpura. J Obs Gynaecol Can. 2010;32(12):1167–1171.
PubMedGoogle Scholar
Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol. 2011;19(14):3438–3442.
Google Scholar
Martínez-Martínez MU, Baranda-Cándido L, González-Amaro R, et al. Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman. Rheumatol (United Kingdom). 2013;52(2):405–406.
PubMed Web of Science ®Google Scholar
Mandal PK, Dolai TK, Bagchi B, et al. B cell suppression in newborn following treatment of pregnant diffuse large B-cell lymphoma patient with rituximab containing regimen. Indian J Pediatr. 2014;81(October):1092–1094.
PubMed Web of Science ®Google Scholar
Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol [Internet]. 2004;72(4):292–295. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15089769
PubMed Web of Science ®Google Scholar
Pellkofer HL, Suessmair C, Schulze A, et al. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler. 2009;15(8):1006–1008.
PubMed Web of Science ®Google Scholar
Ponte P, Lopes MJP. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol. 2010;63(2):355–356.
PubMed Web of Science ®Google Scholar
Ringelstein M, Harmel J, Distelmaier F, et al. Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum. Mult Scler [Internet]. 2013;19(11):1544–1547. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23886825
PubMed Web of Science ®Google Scholar
Pendergraft WF, McGrath MM, Murphy AP, et al. Fetal outcomes after rituximab exposure in women with autoimmune vasculitis. Ann Rheum Dis [Internet]. 2013;72(12):2051–2053. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23864238
PubMed Web of Science ®Google Scholar
Ojeda-Uribe M, Gilliot C, Jung G, et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. J Perinatol. 2006;26(4):252–255.
PubMed Web of Science ®Google Scholar
Chakravarty E, Langen E, Druzin M, et al. High rate of preterm birth in pregnancies complicated by rheumatoid arthritis. Am J Obstet Gynecol Conf [Internet]. 2011;204(1 Suppl).
Google Scholar
Wehner NG, Shopp G, Osterburg I, et al. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol [Internet]. 2009;86(2):144–156. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19283860
PubMed Web of Science ®Google Scholar
Slatter MA, Gennery AR. Clinical immunology review series: an approach to the patient with recurrent infections in childhood. Clin Exp Immunol. 2008;152(3):389–396.
PubMed Web of Science ®Google Scholar
Atkinson AR, Roifman CM. Low serum immunoglobulin G2 levels in infancy can be transient. Pediatrics. 2007;120(3):e543–e547.
PubMed Web of Science ®Google Scholar
Johnson D, Luo Y, Jones KL, et al. Pregnancy outcomes in women exposed to adalimumab: an update on the autoimmune diseases in pregnancy project. Arthritis Rheum Conf Annu Sci Meet Am Coll Rheumatol Assoc Rheumatol Heal Prof [Internet]. 2011;63(10 Suppl. 1).
Google Scholar
van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second european evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn’s Colitis [Internet]. 2014;9(2):107–124. Available from: http://ecco-jcc.oxfordjournals.org/cgi/doi/10.1093/ecco-jcc/jju006
Web of Science ®Google Scholar

•• Updated ECCO statements on the safety, pregnancy outcomes and vaccination of newborns exposed to anti-TNFs

Mahadevan U, Cucchiara S, Hyams JS, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol [Internet]. 2011;106(2):214–23; quiz 224. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21157441
PubMed Web of Science ®Google Scholar

••The London Position Statement on the pregnancy outcomes and vaccinations of infants and mothers exposed to biologicals during pregnancy

Akinsanya-Beysolow I, on Immunization Practices (ACIP) AC, Group ACIW, for Disease Control C, (CDC) P. Advisory Committee on Immunization Practices recommended immunization schedules for persons aged 0 through 18 years – United States, 2014. MMWR Morbidity Mortal Wkly Rep. 2014;63(5):108–109.
PubMed Web of Science ®Google Scholar
Canada PHA. Canadian immunization guide (online). 2015 Jun 13.
Google Scholar
Moses J, Alkhouri N, Shannon A, et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol [Internet]. 2012;107(1):133–138. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21876562
PubMed Web of Science ®Google Scholar
Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep [Internet]. 2010;59(RR–8):1–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20689501
PubMedGoogle Scholar
Woerner A, Sauvain M-J, Aebi C, et al. Immune response to influenza vaccination in children treated with methotrexate or/and tumor necrosis factor-α inhibitors. Hum Vaccin. 2011;7(12):1293–1298.
PubMed Web of Science ®Google Scholar
Lu Y, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. Gastroenterol Hepatol (N Y) [Internet]. 2014;10(6):355–363. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4080872&tool=pmcentrez&rendertype=abstract
PubMedGoogle Scholar

• Information on vaccinating children receiving immunosuppressive therapies, including biologicals

Publication WHO. Hepatitis B vaccines: WHO position paper–recommendations. Vaccine. 2010;28(3):589–590.
PubMedGoogle Scholar
Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J [Internet]. 2012;12(3):228–243. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3448245&tool=pmcentrez&rendertype=abstract
PubMedGoogle Scholar
Avanzini MA, Carra AM, Maccario R, et al. Immunization with Haemophilus influenzae type b conjugate vaccine in children given bone marrow transplantation: comparison with healthy age-matched controls. J Clin Immunol. 1998;18(3):193–201.
PubMed Web of Science ®Google Scholar
Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58(3):309–318.
PubMed Web of Science ®Google Scholar
Shetty AK, Winter MA. Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation. Ochsner J [Internet]. 2012;12(3):228–243. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3448245&tool=pmcentrez&rendertype=abstract
PubMedGoogle Scholar
Tamma P. Vaccines in immunocompromised patients. Pediatr Rev [Internet]. 2010;31(1):38–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20048039
PubMedGoogle Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy

References

• Four cases of severe and moderate neonatal neutropenia in newborns exposed to infliximab in utero are described

• A recently published study with 1-year follow-up outcomes among children born to mothers from anti-tumor necrosis factor (TNF) early stop group, continue group and non-inflammatory bowel disease control group.

• A large PIANO registry long-term report on the first-year infection rate of infants prenatally exposed to anti-TNFs and natalizumab

• A long-term study on the immune development of infants prenatally exposed to anti-TNF agents

•• Updated ECCO statements on the safety, pregnancy outcomes and vaccination of newborns exposed to anti-TNFs

••The London Position Statement on the pregnancy outcomes and vaccinations of infants and mothers exposed to biologicals during pregnancy

• Information on vaccinating children receiving immunosuppressive therapies, including biologicals

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy

References

• Four cases of severe and moderate neonatal neutropenia in newborns exposed to infliximab in utero are described

• A recently published study with 1-year follow-up outcomes among children born to mothers from anti-tumor necrosis factor (TNF) early stop group, continue group and non-inflammatory bowel disease control group.

• A large PIANO registry long-term report on the first-year infection rate of infants prenatally exposed to anti-TNFs and natalizumab

• A long-term study on the immune development of infants prenatally exposed to anti-TNF agents

•• Updated ECCO statements on the safety, pregnancy outcomes and vaccination of newborns exposed to anti-TNFs

••The London Position Statement on the pregnancy outcomes and vaccinations of infants and mothers exposed to biologicals during pregnancy

• Information on vaccinating children receiving immunosuppressive therapies, including biologicals

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date